Amalia M Issa

Summary

Affiliation: Southern Illinois University School of Medicine
Country: USA

Publications

  1. ncbi Ethical perspectives on pharmacogenomic profiling in the drug development process
    Amalia M Issa
    Clinical Ethics Center, Memorial Medical Center, Southern Illinois University School of Medicine, 701 North First Street, Springfield, Illinois 62781 0001, USA
    Nat Rev Drug Discov 1:300-8. 2002
  2. ncbi The regulation of pharmacogenomics-based drugs and policy making
    Amalia M Issa
    UCLA School of Public Health, CHS Room 31 245A, Box 951772, Los Angeles, CA 90095 1772, USA
    Curr Top Med Chem 4:1455-60. 2004
  3. ncbi Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges
    Amalia M Issa
    UCLA School of Public Health, Room 31 245A CHS, Campus Box 951772, Los Angeles, CA 90095 1772, USA
    Pharmacogenomics 4:647-55. 2003
  4. ncbi Diagnostics and biomarker development: priming the pipeline
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 5:463-9. 2006

Detail Information

Publications4

  1. ncbi Ethical perspectives on pharmacogenomic profiling in the drug development process
    Amalia M Issa
    Clinical Ethics Center, Memorial Medical Center, Southern Illinois University School of Medicine, 701 North First Street, Springfield, Illinois 62781 0001, USA
    Nat Rev Drug Discov 1:300-8. 2002
    ..Recommendations are offered for addressing the issues that are discussed and anticipating the regulatory needs for pharmacogenomics-based trials...
  2. ncbi The regulation of pharmacogenomics-based drugs and policy making
    Amalia M Issa
    UCLA School of Public Health, CHS Room 31 245A, Box 951772, Los Angeles, CA 90095 1772, USA
    Curr Top Med Chem 4:1455-60. 2004
    ..Hypothetical vignettes are used to illustrate a number of issues that are challenging to policy makers and the potential impact of pharmacogenomic based drug research and development on the regulatory environment...
  3. ncbi Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges
    Amalia M Issa
    UCLA School of Public Health, Room 31 245A CHS, Campus Box 951772, Los Angeles, CA 90095 1772, USA
    Pharmacogenomics 4:647-55. 2003
    ..A critical analysis of some of the methodological design and ethical issues generated by the potential incorporation of pharmacogenomic profiling into pharmacosurveillance programs is presented...
  4. ncbi Diagnostics and biomarker development: priming the pipeline
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 5:463-9. 2006
    ..Here, we characterize the pipeline problem for biomarkers and diagnostics, and consider what steps could be taken to solve it...